Product Description
a biosimilar to Bevacizumab (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03115762)
Mechanisms of Action: VEGF Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Aosaikang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03115762 |
ASK-LC-B1202-1 | P1 |
Unknown status |
Healthy Volunteers |
2017-07-01 |
2019-04-03 |
Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|